Market intelligence for the peptide supply chain
Capacity · India

Neuland outlines timeline for peptide manufacturing ramp-up

November 9, 2026 · TideMetrix Brief
TideMetrix TakeNeuland's commissioned peptide facility could take another 18–24 months to generate commercial revenue, highlighting the long road from installed manufacturing capacity to qualified peptide API supply.

Neuland Laboratories expects to begin generating revenue from peptide manufacturing validation work within six to nine months, while commercial peptide revenue could remain 18–24 months away.

The Indian manufacturer outlined the timetable during its November 3 earnings call, whose transcript was filed on November 6.

Neuland said its peptide facility has been commissioned and is already generating development revenue, although those revenues remain modest.

Management expects process performance qualification (PPQ) activities to provide another source of revenue within six to nine months. PPQ involves demonstrating that a manufacturing process can consistently produce material meeting predetermined quality requirements, an important step before commercial production.

Asked whether commercial peptide revenue could be approximately 1.5–2 years away, chief executive Saharsh Davuluri described that as a reasonable expectation.

The company is developing its peptide business around a portfolio of customer programmes, with a small number progressing through development and qualification. Management expects to absorb some idle-capacity costs during the ramp-up rather than recover them automatically from customers.

Further expansion will depend on utilization of the first manufacturing module and the requirements of emerging customer projects. Neuland has not committed to a timetable for additional modules.

The guidance illustrates an important distinction for peptide API buyers: commissioning a manufacturing facility does not immediately translate into qualified commercial supply. Revenue from validation batches and development work precedes the larger commercial opportunity, which remains dependent on customer approvals and successful programme progression.

Sources

← Back to News